Boehringer Ingelheim
Also known as: Alberta Boehringer Ingelheim Collaboration | BEN VENUE | B.I. Pharmaceuticals,Inc./Ridgefield | BI Pharma Ges mbH Wien | Boehringer Ingelheim | Boehringer-Ingelheim | BOEHRINGER INGELHEIM | Boehringer Ingelheim BV/Alkmaar | Boehringer Ingelheim (Canada) LTD | Boehringer Ingelheim KG | Boehringer Ingelheim laboratory | Boehringer Ingelheim Ltd./Bracknell | Boehringer Ingelheim Pharmaceuticals, Inc. | BOEHRINGER INGELHEIM PHARMACEUTICALS INC | Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Shanghai | Boeringer Ingelheim | Nippon Boehringer Ingelheim Co., Ltd.
Highest phase reached
Phase 4
First clinical trial
Feb 1, 1990First marketed drug
Jun 1, 1956First NDA
Jun 1, 1956Last known activity
Feb 28, 2026
Timeline
1880s
- Jan 1, 1885
Boehringer Ingelheim— Founded
1970s
- Jan 1, 1978
Columbus Pharmaceutical Company— Acquired
- Jan 1, 1978
Roxane Laboratories— Acquired
1990s
- Jan 1, 1998
Dr. Karl Thomae GmbH— Acquired
2000s
- Jan 1, 2008
Actimis Pharmaceuticals— Acquired
2010s
- Aug 1, 2014
empagliflozin— NDA Secondary Org
- Aug 1, 2014
empagliflozin— NDA Organization
- Mar 29, 2019
ICD Therapeutics— Acquired
- Jul 15, 2019
Amal Therapeutics— Acquired
2020s
- May 14, 2020
Northern Biologics Inc.— Acquired
- Sep 21, 2021
Abexxa Biologics— Acquired
- Dec 17, 2021
NBE-Therapeutics AG— Acquired
- Aug 8, 2025
zongertinib— Marketing Organization
Drugs by trial phase (537 distinct, 2214 trials)
Phase 4 (70 own, 12 via acquisition)
Phase 3 (109 own, 2 via acquisition)
Phase 2 (100 own, 6 via acquisition)
Phase 1 (204 own, 14 via acquisition)
Other trials (1 own, 19 via acquisition)
Indications
Approved for
- Arrhythmias, Cardiac
- Arthritis, Juvenile
- Arthritis, Rheumatoid
- Atrial Fibrillation
- Bronchial Spasm
- Bronchitis, Chronic
- Carcinoma, Non-Small-Cell Lung
- Common Cold
- Coronary Artery Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Embolism
- Emphysema
- Hemorrhage
- HIV Infections
- Idiopathic Pulmonary Fibrosis
- Muscle Cramp
- Obesity
- Osteoarthritis
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Embolism
- Stroke
- Thromboembolism
- Venous Thrombosis
Studied for
- Abdominal Pain
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Acute Disease
- Acute Lung Injury
- Acute Pain
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Adenocarcinoma of Lung
- Adenomyoepithelioma
- Albuminuria
- Alzheimer Disease
- Angina Pectoris
- Angina, Stable
- Anthracosis
- Anxiety Disorders
- Appendiceal Neoplasms
- Arteriosclerosis
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asbestosis
- Asthma
- Astrocytoma
- Atrial Fibrillation
- Atrial Flutter
- Atrophy
- Back Pain
- Borderline Personality Disorder
- Brain Neoplasms
- Breast Neoplasms
- Bronchial Spasm
- Bronchiectasis
- Bronchitis
- Bronchitis, Chronic
- Candidiasis
- Candidiasis, Oral
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Cerebral Infarction
- Cholangiocarcinoma
- Chordoma
- Chronic Pain
- Cognition Disorders
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colorectal Neoplasms
- Common Cold
- Communicable Diseases
- Constipation
- Coronary Artery Disease
- Coronary Disease
- Coronavirus Infections
- Crohn Disease
- Cystadenocarcinoma, Serous
- Cystic Fibrosis
- Dementia
- Depression
- Depressive Disorder
- Dermatitis
- Dermatitis, Atopic
- Diabetes, Gestational
- Diabetes Mellitus
- Diabetes Mellitus, Lipoatrophic
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Neuropathies
- Diabetic Retinopathy
- Diarrhea
- Digestive System Diseases
- Digestive System Neoplasms
- Disease
- Disease Progression
- Dyslipidemias
- Dysmenorrhea
- Dyspnea
- Dyssomnias
- Edema
- Embolism
- Emergencies
- Enuresis
- Esophageal Neoplasms
- Essential Hypertension
- Fallopian Tube Neoplasms
- Familial Primary Pulmonary Hypertension
- Fatigue
- Fatty Liver
- Fibromyalgia
- Fibrosis
Marketed drugs (81)
Subsidiaries (9 direct, 9 total across the full acquisition tree)
Recent trials (50)
- NCT05624281Lead sponsorN/A—
- NCT05107193Lead sponsorN/A—
- NCT04739150Lead sponsorN/A—
- NCT03843892Lead sponsorN/A—
- NCT07304817CollaboratorPhase 2Feb 28, 2026
- NCT07308652Lead sponsorPhase 1Feb 9, 2026
- NCT07306559Lead sponsorPhase 1Jan 29, 2026
- NCT07201922Lead sponsorPhase 3Jan 23, 2026
- NCT07074418CollaboratorPhase 4Dec 31, 2025
- NCT07176975Lead sponsorPhase 1Dec 18, 2025
- NCT07273474Lead sponsorPhase 1Dec 15, 2025
- NCT07107945Lead sponsorPhase 3Dec 12, 2025
- NCT07195695Lead sponsorPhase 3Dec 5, 2025
- NCT07220083Lead sponsorPhase 3Dec 5, 2025
- NCT07250048Lead sponsorPhase 1Nov 20, 2025
Details
- Founded
- Ingelheim am Rhein, DE Jan 1, 1885
- First NDA
- Jun 1, 1956
- Last known activity
- Feb 28, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval